Saturday 17 October 2026
Export RNLXY’s income statement to Excel — free account
Renalytix plc - Sponsored ADR
RNLXY Healthcare Health Information Services
Renalytix plc - Sponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $3.0 million, up 30.4% from fiscal 2024. Operating cash flow growth for three consecutive years.
3.50
0.11
+3.24%
Follow RNLXY
| Jun '25 | Dec '24 | Sep '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 3 | 2 |
+8 more TTM periods Free account |
| — | 0.00% | 625.67% | 4,476.14% | ||
| 0.00% | 0.00% | (329.37%) | (241.19%) | ||
ROIC |
— | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | 0.00% | 448.66% | 947.92% | |
Average Days of Receivables |
— | 0.00 | 139.33 | 111.09 | |
Free Cash Flow per Share |
— | 0.00 | (11.42) | (13.88) | |
Free Cash Flow |
— | (22.71) | (24.13) | (30.07) | |
Capital Expenditures |
— | — | — | (0.27) | |
| Other line items | |||||
Cash ROIC |
— | (137.41%) | 382.44% | (4,295.86%) | |
Accounts Receivable Turnover |
— | 0.00 | 2.47 | 3.12 | |
Accounts Payable Turnover |
— | 0.00 | 0.45 | 0.40 | |
Inventory Turnover |
— | 0.00 | 0.00 | 10.31 | |
Average Days of Payables |
— | 0.00 | 1,011.16 | 1,320.95 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 52.14 | |
Tax Rate |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | 314.18% | 403.91% | |
Selling, General and Administrative Expense of Revenue |
— | — | 1,181.21% | 1,334.78% | |
Share Based Compensation of Revenue |
— | 0.00% | 35.17% | 47.83% | |
Operating CF/Net income |
— | 0.00 | 0.60 | 0.65 | |
Depreciation/Fixed assets |
— | 12.25 | 12.04 | 12.50 | |
Capex/Depreciation |
— | 0.00 | 0.00 | (0.11) | |
Revenue per Share |
— | — | 1.12 | 1.06 | |
Operating CF per Share |
— | 0.00 | (11.42) | (13.75) | |
Capex per Share |
— | — | 0.00 | (0.13) | |
Capex to Sales |
— | — | 0.00 | 0.12 |
Columns are period end dates